Truist Financial Sticks to Its Buy Rating for Mersana Therapeutics (MRSN)
Analysts Have Conflicting Sentiments on These Healthcare Companies: Mersana Therapeutics (MRSN), Insulet (PODD) and Crispr Therapeutics AG (CRSP)
Truist Financial Sticks to Their Buy Rating for Mersana Therapeutics (MRSN)
Mersana Therapeutics Analyst Ratings
Mersana Therapeutics (MRSN) Gets a Buy From Truist Financial
Buy Rating Affirmed for Mersana Therapeutics Amid Promising ADC Developments and Upcoming Milestones
Mersana Therapeutics Analyst Ratings
TD Cowen Sticks to Its Buy Rating for Mersana Therapeutics (MRSN)
Mersana Therapeutics: A Cautious Hold Amid Clinical and Strategic Uncertainties
BTIG Sticks to Their Hold Rating for Mersana Therapeutics (MRSN)
Citigroup Upgrades Mersana Therapeutics to Buy, Raises Price Target to $5
Mersana Therapeutics Analyst Ratings
Hold Rating on Mersana Therapeutics Amidst Clinical Trial Progress and Solid Financial Position
Analysts Offer Insights on Healthcare Companies: CymaBay Therapeutics (CBAY), Mersana Therapeutics (MRSN) and Verona Pharma (VRNA)
Mersana Therapeutics (MRSN) Gets a Hold From BTIG
Analysts Have Conflicting Sentiments on These Healthcare Companies: Mersana Therapeutics (MRSN) and Crispr Therapeutics AG (CRSP)
Analysts Have Conflicting Sentiments on These Healthcare Companies: Mersana Therapeutics (MRSN), Applied Therapeutics (APLT) and Align Tech (ALGN)
Mersana Therapeutics (MRSN) Receives a Hold From Truist Financial
Mersana Therapeutics (MRSN) Gets a Hold From Robert W. Baird
Analysts Conflicted on These Healthcare Names: Laboratory (LH), Hologic (HOLX) and Mersana Therapeutics (MRSN)